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patient-reported outcome (PRO) instruments in clinical trials, as
recommended in the FDA draft guidance for industry. A system-
atic review of PROs assures that the best available instrument is
used to measure the preferred endpoint. As systematic reviews are
scientiﬁc exercises, they require the same rigour as other aspects of
research, yet current methods used to conduct systematic reviews
remain variable, meaning that the quality and comparability of
such reviews is not assured. Our aim was to explore the compre-
hensiveness, understandability, and adaptability of two widely
used methodologies in conducting and modifying a standard
search. METHODS: We compared the most common systematic
review method (syntax search) and the Cochrane-collaboration
recommended “Population-Intervention-Comparator-Outcome”
(PICO) strategy. SCOPUS was searched using terms devised to
answer the research question “which PROs have been used to date
in islet cell transplantation?” The output resulting from each
strategy was independently evaluated by two researchers and the
methods critiqued. RESULTS: Both methods returned 6486
abstracts for review. Researchers were asked to identify ways in
which to combine search terms to present a more manageable
number for abstract screening. Both researchers agreed that PICO
allowed for greater adaptability and targeted reviewing without
compromising quality. Combining a priori search terms system-
atically according to [P and (I or C) and O], resulted in 359
abstracts. CONCLUSIONS: The quality of a review depends on
the extent to which scientiﬁc reviewmethods are used to minimise
the risk of error and bias, but also the extent to which the search
strategy is replicable and ﬂexible. The PICO method is compa-
rable to the standard syntax search, but offers the added beneﬁts
of being easy to implement, and sufﬁciently versatile to allow
further targeting according to subtle changes in the research
question as desired.
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OBJECTIVES: Confounding is a common source of bias in
outcome studies involving observational non-randomized data.
The propensity scores methodology has been suggested as a
good analytical approach for handling this problem without any
indication on whether a threshold exits on its predictive ability.
We investigate the usefulness of the C-statistic in this regard
using simulated data. METHODS: In each simulation, we gen-
erated 100 sets of 10,000 patients; each patient being assigned
probabilities of being treated and of experiencing the outcome
of interest. The process involved two logistic models, one that
related treatment to a set of 10 independent covariates and the
other relating outcome to treatment and the same 10 covariates,
using Bernoulli distributions that assumed an odd ratio (OR)
for treatment between 0.14 to 1.00 for each dataset. Propensity
scores from each dataset were estimated and propensity scores-
matched analysis conducted using conditional logistic regression
to estimate the OR and from the 100 sets, we obtained the
mean, median and bias in the estimate. Bias was deﬁned as the
difference between actual and estimated ORs as a proportion of
actual. RESULTS: We found evidence of correlation between
the levels of bias in the OR estimates and the C-statistics, with
level often exceeding 300% when the C-statistic was less than
80%. CONCLUSIONS: Where as an elevated value of the
C-Statistic may not guarantee effective correction of confound-
ing by the resultant propensity scores derived from a given data,
our study indicates that a lower value does indicate a poor
capability. We suggest the C-Statistic can be adopted as a simple
reporting tool on the propensity scores model in respect of its
efﬁciency.
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OBJECTIVES: One of the existing methods to assess the trans-
ferability of economic evaluations is the model of Welte, which is
a decision chart method that includes general and speciﬁc knock-
out criteria and a transferability checklist. This study aims to
validate Welte’s model with the help of a case study. METHODS:
In this study, foreign studies were transferred to The Netherlands
and then compared with a Dutch reference study. Using the case
study on non-speciﬁc subacute and chronic low back pain, the
cost-effectiveness of physiotherapy was compared with a multi-
disciplinary treatment. With the help of a systematic search
several foreign studies could be identiﬁed. Based on these foreign
studies two different predictions regarding costs, effects and cost-
effectiveness were produced for The Netherlands. In the “all
studies predictions” all foreign studies were used. In the “Welte’s
model predictions” only the foreign studies were used which
passed the general and speciﬁc knock-out criteria. Both predic-
tions were compared with the Dutch reference case. RESULTS: A
total of fourteen non-Dutch studies were identiﬁed. Seven studies
did not pass the general knock-out criteria and one study did not
pass the speciﬁc knock-out criteria. The decision if a study was
transferable was based on double retriever scores. As a result
fourteen studies were included in the “all studies prediction” and
six studies in the “Welte’s model prediction”. The predictions
yielded different results and the “Welte’s model prediction”
proved better on costs than the “all studies prediction”. The
effectiveness predictions were least accurate for the “Welte’s
model prediction”. Because of the small effectiveness difference
no ICER predictions were calculated. DISCUSSION: Application
of the model of Welte does inﬂuence cost and effects estimates
when transferring economic data between countries. However,
more cases should be subjected to the Welte transferability model
before a ﬁnal conclusion can be drawn.
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OBJECTIVES: Economic evaluations are preferably performed
from a societal perspective. This implies that participants report
their health care utilization continuously during follow-up.
Because this is a burden to participants, often resulting in missing
values or withdrawal, researchers advocate collecting data dis-
continuously (i.e. in at least three months a year). This study
aimed to compare costs of discontinuous measurement of health
care utilization with those of continuous measurement, using
several discontinuous measurement patterns and three imputa-
tion techniques: Individual Mean (IM), Last Observation Carried
Forward (LOCF) and Next Observation Carried Backward
(NOCB). METHODS: We used continuous health care utiliza-
tion data from a trial with twelve months’ follow-up and simu-
lated several discontinuous measurement patterns combined with
different imputation methods, to calculate simulated annual
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volumes and costs. Correlations and paired T-tests were used to
compare simulated annual costs with actual annual costs from
the continuous measurements. RESULTS: Analyses conﬁrmed
that discontinuous measurements using cost diaries offer good
estimates of annual health expenditures, but measurement pat-
terns and imputation methods did inﬂuence the outcomes, as the
correlations differed between methods. The best estimated
annual costs were obtained by random cohort measurement,
using three random cohorts, ensuring that at least a third of the
participants were measuring costs each month, combined with
IM imputation. Discontinuous measurement of health expendi-
tures carries a small risk of missing infrequent expensive events,
which may result in underestimation of annual costs. CONCLU-
SIONS: To reduce the burden on participants in future economic
evaluation, we recommend calculating annual costs from discon-
tinuous measurements in random cohorts, combined with IM
imputation.
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OBJECTIVES: Appropriate design and efﬁcient analytical strat-
egy are generally considered as some of the prerequisites for a
valid and reliable health outcomes research on non-randomized
observational data. For rare outcomes, the case-control design is
often presented as the most efﬁcient, whereby, proper selection of
controls is crucial. Using simulated data for the nested case-
control design, we assess the relative efﬁciencies of two sampling
strategies for the controls- the version where controls can never
be cases (design 1) and the recommended approach in which
controls are sampled from the risk sets such that some controls
can be future cases (design 2). METHODS: In each simulation,
we assumed an underlying hazard that follows a Weibull distri-
bution with inputted values for the scale and shape parameters to
generate 100 sets of cohorts of 4000 patients in treatment groups
(i.e. treated and untreated). The process also involved an
assumed hazard ratio for treatment and 3 factors that required
adjustments. Designs 1 and 2 were then applied successively on
each of the resulting datasets and then analysed to obtained for
each design, the estimated odds ratio (OR- an approximate of the
inputted hazard ratio) and its 1st and 3rd quartiles. RESULTS: We
considered over 50 scenarios for hazard ratio that varied between
0.3 and 4.0. The absolute differences between the inputted
hazard ratio and the estimated odd ratio ranged from 0.01–8.00
and from 0.01–0.50 for designs 1 and 2 respectively. The input-
ted hazard ratio was within the inter-quartile range of the OR in
less than 5% of the runs with design 1 but more than 80% with
design 2. CONCLUSIONS: Our study suggests that in nested
case-control designed studies, if controls are not sampled from
the appropriate risk sets, we can expect much larger bias in our
estimates than with correct sampling.
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OBJECTIVES: Economic analyses in health technology assess-
ment often require estimation of absolute risk difference (ARD)
for outcomes such as survival or progression, given base risk in
the jurisdiction of interest and trial evidence of treatment effects.
We demonstrate that odds ratios (OR) provide distinct advan-
tages over relative risk (RR) in consistently estimating such ARD
independent of the framing of effects (e.g. mortality or survival)
for direct and indirect comparisons. METHODS: Use of RR is
shown to lead to inferential anomalies in estimating ARD, while
consistently estimated using OR. These inferential anomalies and
odds solution are illustrated for indirect comparison of Natiluz-
imab versus Interferon beta-1b for multiple sclerosis, as well as
direct comparisons. RESULTS: Standard use of relative risk to
calculate ARD in indirect comparison suggests Natiluzimab is
more effective than Interferon for progression (RR = 0.70, ARD
= 21% for a base risk of 70% progression) but less effective than
Interferon for no progression (RR = 0.84, ARD = 4.8%). This
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